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Deficiency of NADH:ubiquinone oxidoreductase or complex I (CI) is the most common cause of disorders of the oxidative phosphorylation
system in humans. Using life cell imaging and blue-native electrophoresis we quantitatively compared superoxide production and CI amount and
activity in cultured skin fibroblasts of 7 healthy control subjects and 21 children with inherited isolated CI deficiency. Thirteen children had a
disease causing mutation in one of the nuclear-encoded CI subunits, whereas in the remainder the genetic cause of the disease is not yet
established. Superoxide production was significantly increased in all but two of the patient cell lines. An inverse relationship with the amount and
residual activity of CI was observed. In agreement with this finding, rotenone, a potent inhibitor of CI activity, dose-dependently increased
superoxide production in healthy control cells. Also in this case an inverse relationship with the residual activity of CI was observed. In sharp
contrast, however, rotenone did not decrease the amount of CI. The data presented show that superoxide production is increased in inherited CI
deficiency and that this increase is primarily a consequence of the reduction in cellular CI activity and not of a further leakage of electrons from
mutationally malformed complexes.
© 2007 Elsevier B.V. All rights reserved.Keywords: Fibroblast; Mitochondria; Hydroethidine; Rotenone; Fluorescence microscopy1. Introduction
The mitochondrial oxidative phosphorylation (OXPHOS)
system consists of five multiprotein complexes: NADH:Abbreviations: CI, complex I or NADH:ubiquinone oxidoreductase; CII,
complex II or succinate dehydrogenase-ubiquinone oxidoreductase; CIII,
complex III or ubiquinol:cytochrome c oxidoreductase; CIV, complex IV or
cytochrome c oxidase; OXPHOS, oxidative phosphorylation; HEt, hydroethi-
dine; Δψ, mitochondrial membrane potential
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E-mail address: j.smeitink@cukz.umcn.nl (J.A.M. Smeitink).
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doi:10.1016/j.bbadis.2006.12.009ubiquinone oxidoreductase (complex I or CI), succinate-
dehydrogenase-ubiquinone oxidoreductase (CII), ubiquinol:
cytochrome c oxidoreductase (CIII), cytochrome c oxidase
(CIV) and F0F1-ATP synthase (CV) [1]. The first 4 complexes
(CI–CIV), together with 2 electron carriers (coenzyme Q10 and
cytochrome c), constitute the respiratory chain that utilizes the
energy of NADH and succinate, oxidized at CI and CII,
respectively, to translocate protons from the mitochondrial
matrix into the intermembrane space. The latter results in a
negative potential (Δψ) across the inner mitochondrial mem-
brane, which is crucial for the maintenance of mitochondrial
integrity [2].
Dysfunction of the OXPHOS system is associated with a
wide array of clinical manifestations, ranging from single
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inherited nonsyndromic deafness to more widespread lesions
including myopathies, encephalomyopathies, cardiopathies, or
complex multisystem syndromes [3–6]. Inherited disorders of
the OXPHOS system are observed once every 10,000 live
births and the most frequently occurring enzymatic deficiency
is found in CI (EC 1.6.5.3), which catalyzes the transfer of
electrons from NADH to coenzyme Q10. In human heart, this
complex consists of at least 45 different subunits, together
having a molecular weight close to 1 MDa [7]. With the aid
of differential extraction techniques, CI can be subdivided
into a flavoprotein (FP), iron–sulfur protein (IP) and
hydrophobic protein (HP) fraction. The catalytic core of the
complex comprises 14 evolutionary conserved subunits, 2 of
which reside in the FP fraction, 5 in the IP fraction and 7 in
the HP fraction [8]. In humans, these core subunits are
encoded by the nuclear NDUFV1 and NDUFV2 genes, the
nuclear NDUFS1, NDUFS2, NDUFS3, NDUFS7 and
NDUFS8 genes and the mitochondrial ND1–ND6 and ND4L
genes. Thus far, disease causing mutations have been identified
in all 14 core subunits [1] and, as far as the nuclear genome is
concerned, in genes encoding supernumerary subunits
NDUFS4 [1] and NDUFS6 [9] and assembly factor B17.2L
[10].
The pathophysiological mechanisms linking defects in CI
genes to cellular dysfunction and disease are only partially
understood. To obtain insight into these mechanisms, we use
skin fibroblasts of patients with inherited isolated CI deficiency
and study the biogenesis of CI and cytopathological conse-
quences of its dysfunction. Native gel electrophoresis and in-gel
activity assays revealed that mutations in CI subunits
(NDUFS2, NDUFS4, NDUFS7 and NDUFS8) markedly
reduced the expression of the fully assembled, catalytically
active complex [11]. At the cell physiological level, this
reduction was found to be associated with disturbed mitochon-
drial Ca2+ handling and ensuing ATP production during
hormone stimulation [12,13].
Partial inhibition of CI activity by chronic treatment with
rotenone significantly increased superoxide production and
lipid peroxidation in cultured skin fibroblasts of healthy control
subjects [14]. Similarly, the formation of superoxide-derived
hydroxyl radicals and lipid peroxidation products was found to
be increased in fibroblasts of three patients with a reduced
rotenone-sensitive NADH-cytochrome c reductase (CI and
CIII) activity [15]. At pathological concentrations, superoxide
and its derived reactive oxygen species are hazardous for the
cell. At physiological concentrations, however, they play
important roles in a variety of signaling processes [16]. In
fibroblasts of healthy control subjects we observed that the
increase in superoxide production induced by chronic rotenone
treatment was associated with a marked increase in mitochon-
drial length and degree of branching [14]. Moreover, in patient
fibroblasts we found that this parameter was linearly correlated
with the residual activity of CI [17]. Based on these
observations, we hypothesized that the increase in mitochon-
drial length and degree of branching constitutes an adaptive
response to protect against the consequences of CI deficiency.In agreement with this idea, recent evidence showed that a more
complex mitochondrial network, induced by manipulating
mitochondrial fusion, protected against radical-induced mito-
chondrial depolarization possibly by allowing a more effective
sharing of intra-mitochondrial antioxidants [18].
To obtain a quantitative understanding of the relationship
between CI deficiency and superoxide production, we here
compare superoxide production and amount and activity of CI
between cultured skin fibroblasts of 7 healthy control subjects
and 21 children with inherited isolated CI deficiency. The data
presented show that superoxide production is increased in
virtually all patient cell lines but to a variable degree and that the
extent of increase is inversely proportional to the amount and
activity of CI.
2. Materials and methods
2.1. Patient skin fibroblasts
Fibroblasts were derived from skin biopsies of 21 CI deficient children in the
age range of 0–5 years, 2 age-matched healthy children and 5 healthy adults
following informed consent and according to relevant institutional review
boards [19]. Table 1 shows that superoxide production did not differ between
adult (CT1–CT5) and age-matched (CT6 and CT7) control cell lines. For 11
patients the biochemical analysis, mutations and clinical phenotypes were
described before (P1, P2 [20]; P4–P6 [21]; P7, P8, P9, P11 [22]; P12 [23]), for 3
patients (P3, P10, P13) these data are not yet reported, whereas for the remaining
8 patients the mutations are hitherto unknown (P14–P21 [11]). Fibroblasts were
cultured in medium 199 with Earle's salt supplemented with 10% (v/v) fetal calf
serum, 100 IU/ml penicillin and 100 IU/ml streptomycin in a humidified
atmosphere of 95% air and 5% CO2 at 37 °C. Measurements were performed
within 5 passages after the start of the culture. The passage number at the onset
of the culture is given in Table 1.
2.2. Enzyme activity measurements
Activities of NADH:ubiquinone oxidoreductase (CI; EC: 1.6.5.3) and
cytochrome c oxidase (CIV; EC: 1.9.3.1) were determined in a mitochondrial
enriched fraction of cultured fibroblasts as described previously [24]. The
activity of CI was normalized against that of CIVand expressed as percentage of
lowest control (110 mU/U CIV [19,24]).
2.3. Quantification of superoxide production
Fibroblasts were incubated in HEPES–Tris medium (132 mM NaCl,
4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose and 10 mM
HEPES, pH 7.4), containing 10 μM hydroethidine (HEt; Molecular Probes,
Leiden, The Netherlands) for 10 min at 37 °C. HEt is a lipophylic, uncharged
compound that readily enters the cell where it reacts with superoxide to form
two positively charged products, 2-hydroxyethidium and ethidium, both of
which emit red fluorescence [25]. The reaction was stopped by thorough
washing of the cells with PBS to remove excess HEt. For quantitative
analysis of the fluorescent HEt oxidation products, coverslips were mounted
in an incubation chamber placed on the stage of an inverted microscope
(Axiovert 200M, Carl Zeiss, Jena, Germany) equipped with a Zeiss 40×/1.3
NA fluor objective. The cells were excited at 490 nm using a monochromator
(Polychrome IV, TILL Photonics, Gräfelfing, Germany). Fluorescence
emission light was directed by a 525DRLP dichroic mirror (Omega Optical
Inc., Brattleboro, VT, USA) through a 565ALP emission filter (Omega) onto
a CoolSNAP HQ monochrome CCD-camera (Roper Scientific, Vianen, The
Netherlands). Hardware was controlled with Metafluor 6.0 software
(Universal Imaging Corporation, Downingtown, PA, USA). Routinely, 10
fields of view were analyzed per coverslip using an acquisition time of
100 ms.
Table 1
Characteristics of the complex I deficient fibroblast cell lines
Cell line a Affected subunit and mutation b Clinical
phenotype c
PNd CI
Act e
Superoxide production f
Nucleus Mitochondria
Untreated Rotenone Untreated Rotenone
CT1 (#5120) g None n.a. 17 113 100±1 (n=526) 237±3 (n=516) 100±1 172±2
CT2 (#5119) g None n.a. 17 105 112±3 (n=89) 237±8 (n=89) 102±2 156±6
CT3 (#5118) g None n.a. 21 103 102±2 (n=126) 229±5 (n=127) 98±3 172±5
CT4 (#4996) g None n.a. 10* n.d. 112±3 (n=95) 283±9 (n=89) 100±3 182±5
CT5 (#223V) g None n.a. 8* 103 112±3 (n=94) 286±6 (n=90) 99±3 175±4
CT6 (#5117) h None n.a. 15 223 99±4 (n=92) n.d. 92±3 n.d.
CT7 (#5503) h None n.a. 6* 220 91±3 (n=98) n.d. 93±3 n.d.
P1 (#5171) NDUFV1-R59X/T423M MLM/LL 18 73 214±7 (n=84) 405±10 (n=87) 186±6 281±7
P2 (#5866) NDUFV1-R59X/T423M MLM/LL 18 64 117±4 (n=61) 244±8 (n=58) 110±3 167±8
P3 (#6173) NDUFS1-D618N/R577X L/LD 13* 31 207±5 (n=83) 271±8 (n=71) 176±4 205±6
P4 (#5170) NDUFS2-R228Q HCEM 11* 39 229±7 (n=66) 331±12 (n=69) 205±8 243±8
P5 (#5067) NDUFS2-P229Q HCEM 10* 36 331±10 (n=100) 528±15 (n=108) 264±9 356±10
P6 (#4605) NDUFS2-S413P HCEM 15* 40 301±21 (n=40) 378±18 (n=47) 218±13 272±17
P7 (#5077) NDUFS4-W97X L/LL 23* 59 170±4 (n=100) 339±11 (n=95) 142±4 232±7
P8 (#5260) NDUFS4-R106X L/LL 12 36 196±10 (n=64) 293±8 (n=68) 174±8 203±6
P9 (#4827) NDUFS4-R106X L/LL 7* 58 238±8 (n=93) 398±13 (n=93) 196±6 252±9
P10 (#5737) NDUFS4-VPEEHI67/VEKSIstop L/LL 12 53 150±4 (n=92) 228±6 (n=87) 131±4 166±5
P11 (#4608) NDUFS4-K158fs L/LL 18* 75 207±5 (n=106) 377±9 (n=102) 195±6 270±7
P12 (#5175) NDUFS7-V122M L/LL 15* 68 161±4 (n=94) 322±9 (n=95) 151±5 209±7
P13 (#6603) NDUFS8-R94C L/LL 15 18 263±7 (n=147) 375±9 (n=126) 222±7 267±8
P14 (#4611) Unknown L/LL 14* 36 395±27 (n=36) 581±39 (n=40) 265±19 330±28
P15 (#5409) Unknown FILA 6* 45 265±11 (n=104) 425±22 (n=65) 262±11 340±20
P16 (#4591) Unknown UEM 6* 39 189±5 (n=79) 377±15 (n=60) 159±5 234±11
P17 (#4554) Unknown L/LL 6* 42 175±6 (n=60) 286±11 (n=56) 145±7 192±8
P18 (#4590) Unknown FILA 8* 60 217±7 (n=70) 401±13 (n=59) 204±7 315±15
P19 (#4606) Unknown FILA 6* 63 197±9 (n=42) 302±18 (n=45) 177±10 237±14
P20 (#4617) Unknown L/LL 3* 85 127±5 (n=56) 217±6 (n=64) 131±6 174±7
P21 (#5671) Unknown L/LL 10 27 331±18 (n=38) 402±22 (n=34) 241±15 282±16
Abbreviations: n.a., not appropriate, n.d., not determined.
a Numbers indicate the designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders (NCMD). CT and P indicate control and patient cell
lines, respectively.
b Human subunit designation corresponds to the following nomenclature in Bos taurus: NDUFV1 (51 kDa), NDUFS1 (75 kDa), NDUFS2 (49 kDa), NDUFS4 (18
kDa), NDUFS7 (PSST), NDUFS8 (TYKY). Mutations are given at the protein level.
c FILA: Fatal infantile lactic acidosis, HCEM: Hypertrophic cardiomyopathy and encephalomyopathy, L/LD: Leigh syndrome and leukodystrophy, L/LL: Leigh
syndrome and Leigh-like syndrome, MLM: Macrocephaly, leukodystrophy and myoclonic epilepsy, UEM: Unspecified encephalomyopathy.
d PN: passage number, an asterisk indicates the passage number after arrival at the Nijmegen Center for Mitochondrial disorders.
e CI activity is measured in mitochondrial enriched fractions and expressed as % of lowest control.
f Mean (±SEM) nuclear and mitochondrial fluorescence intensity expressed as percentage of untreated control #5120 (CT1) for the number of cells between
brackets. Each cell line was tested on at least 2 days. Values in bold are below lowest control value (CI activity) or significantly different (p<0.05) from highest
control (CT2; superoxide production). Rotenone indicates acute treatment with 100 nM rotenone during HEt incubation (10 min, 37 °C).
g Cells obtained from healthy adults.
h Cells obtained from healthy age-matched children.
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Cultured skin fibroblasts were harvested by trypsinization, washed, and
resuspended (approximately 2×106 cells) in 100 μl ice-cold PBS. For isolation
of mitochondria, cells were incubated with 2 mg/ml digitonin (Biosciences Inc.,
La Jolla, CA, USA) in a final volume of 200 μl for 10 min on ice. Next, 1 ml ice-
cold PBS was added followed by centrifugation (5 min; 10,000×g; 4 °C).
Mitochondrial pellets were washed twice with 1 ml ice-cold PBS and stored
overnight (−20 °C). Pellets were solubilized in 100 μl ACBT buffer (Fluka,
Steinheim, Germany) containing 1.5 M aminocaproic acid and 75 mMBis–Tris/
HCl (pH 7.0). To extract mitochondrial protein complexes, 20 μl 10% (w/v) β-
lauryl maltoside was added and the solution was incubated for 10 min on ice.
After centrifugation (30 min; 10,000×g; 4 °C), 10 μl of blue-native sample
buffer (Biorad Laboratories, Hercules, CA, USA) was added to the supernatant.
Blue native PAGE (BNP) and Western blotting, using monoclonal antibodies
with human reactivity against the NDUFA9 (39 kDa) subunit of CI (Molecular
Probes) and the 70-kDa subunit of CII (Molecular probes) at a dilution of1:1000, was performed as described previously [26]. For quantitative analysis
gels were loaded with exactly 40 μg of mitochondrial protein. After Western
blotting, luminescent signals were quantitatively analyzed by exposing
illumination films to the blots for different periods of time (5–180 s). Non-
saturating films were scanned using a G690 Imaging Densitometer (Biorad).
From these scans, the integrated optical density of each band was determined
and background corrected. The resulting numerical values were normalized to
those obtained with control cells on the same blot.
2.5. Data analysis
Processing and analysis of fluorescence images and densitometer scans was
performedwith Image Pro Plus 5.1 (Media Cybernetics, SanDiego, CA,USA) and
Metamorph 6.1 (Universal Imaging Corporation, Downingtown, PA, USA).
Numerical results were visualized using Origin Pro 7.5 (OriginLab Corp.,
Northampton, MA, USA) and presented as the mean±SEM. During linear
regression analysis, the degree of bivariate correlation between sets of data was
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total variation that is explained by the regression. If R is ±1, the total variation in the
fit can be explained in terms of the regression curve [27]. ForR>0 the correlation is
positive, for R<0 the correlation is negative. Statistical differences between
average values were determined using an independent two-population Student's
t-test (Bonferroni corrected). P-values <0.05 were considered significant.
2.6. Chemicals
Culture materials were obtained from Invitrogen (Breda, The Netherlands),
all other reagents were from Sigma-Aldrich (St. Louis, MO, USA).3. Results
3.1. Quantitative measurement of superoxide production in
human skin fibroblasts
In this studywe assessed superoxide production in living cells
using hydroethidine (HEt), a membrane-permeable derivative of
ethidium bromide that is specifically converted by superoxide
into 2-hydroxyethidium and ethidium [25,28]. Both products are
positively charged and emit red fluorescence when excited at
490 nm. Human skin fibroblasts were grown to ∼70%
confluence, treated with 10 μM HEt for 10 min and thoroughly
washed to remove non-oxidized HEt. Next, video-imaging
microscopy was used for subcellular quantification of the
fluorescent oxidation products formed during the 10-min
incubation period with HEt. We reported before that the
fluorescent products formed during the oxidation of HEt
accumulated predominantly in the nucleus and a widespread
network of tubular structures located within the cytosol [14]. Fig.
1A shows that in both compartments the average fluorescence
intensity remained stable for at least 200 s, indicating that non-
oxidized HEt was effectively removed during the washing step
and that its oxidation products did not translocate during the
ensuing recording period. In addition, this result demonstrates
that the fluorescent products were resistant to photo-bleaching.
Fig. 1A furthermore shows that dissipation of the mitochondrial
membrane potential by FCCP (p-trifluoromethoxy carbonyl
cyanide phenyl hydrazone; 1 μM) leads to a rapid decrease in
tubular fluorescence. This result identifies the tubular structures
as active mitochondria in which positively charged HEt
oxidation products are retained in a membrane potential-
dependent manner. The FCCP-induced decrease in tubular
fluorescence was mirrored by a concomitant increase in nuclear
fluorescence, indicating the translocation of HEt oxidation
products from the mitochondria to the nucleus. The results
obtained with FCCP demonstrate that HEt oxidation products
can easily pass mitochondrial membranes. Therefore, it is not
possible to make a statement concerning the exact site(s) of
primary HEt oxidation.
3.2. Chronic rotenone treatment dose-dependently increases
superoxide production in human skin fibroblasts
To mimic the pathological condition of chronic CI
deficiency, control fibroblasts were cultured in the presence of
different concentrations (0.1–5000 nM) of rotenone for 72 h[14]. At concentrations at or below 1 nM, this specific inhibitor
of CI had no effect on the amount of fluorescent oxidation
products that accumulated in the mitochondrial compartment
during the 10-min incubation period with HEt (Fig. 1B, closed
circles). At higher concentrations, however, the drug dose-
dependently increased this amount. For the entire range of
rotenone concentrations, mitochondrial and nuclear fluores-
cence were linearly correlated (R=0.98, p<0.0001). The
increase in mitochondrial fluorescence was virtually mirrored
by the decrease in residual CI activity (Fig. 1B, open circles),
determined in a mitochondrial enriched fraction of cultured
fibroblasts (data from [14]). Half-maximal concentrations were
110 nM and 20 nM, respectively. These findings show that in
human skin fibroblasts drug-induced reduction in CI activity is
accompanied by increasing production of cellular superoxide.
3.3. Chronic rotenone treatment increases fully assembled CI
in human skin fibroblasts
We showed before in control fibroblasts that chronic rote-
none treatment (100 nM, 72 h) caused an increase in mito-
chondrial length and degree of branching [14]. Using blue-
native polyacrylamide gel electrophoresis we here show that
this treatment also caused a 1.3-fold increase (p<0.05) in fully
assembled CI (Fig. 1C). In contrast, this treatment did not alter
the amount of CII.
3.4. Superoxide production is increased in patient skin
fibroblasts
The amount of fluorescent oxidation products that accumu-
lated in the mitochondrial compartment during the 10-min
incubation with HEt did not significantly differ between
fibroblasts of seven healthy control subjects (Table 1, CT1–
CT7). Compared to control, however, mitochondrial accumula-
tion of HEt oxidation products was significantly increased in all
but two patient cell lines (P2 and P20). As for healthy control
fibroblasts treated with various concentrations of rotenone,
mitochondrial and nuclear fluorescence were linearly correlated
for the whole cohort of patient cell lines (R=0.98, p<0.0001).
Linear regression analysis furthermore revealed an inverse
relationship betweenmitochondrial fluorescence and residual CI
activity (Fig. 2, R=−0.83, p<0.0001). In all patient cell lines,
acute treatment with 100 nM rotenone (during the 10-min
incubation with HEt) caused a further increase in fluorescence
intensity (Table 1), demonstrating the presence of a functional
rotenone binding site.
3.5. Fully assembled CI is decreased in patient skin fibroblasts
We reported before that the amount of fully assembled CI is
markedly reduced in patient fibroblasts with mutations in
nuclear-encoded CI subunits [11]. Fig. 3 depicts assembly data
of a subgroup of 13 patients, 7 with a known mutation (Table 1,
P1–P5 and P12–P13) and 6 with a hitherto unknown mutation
(Table 1, P14–P16 and P18–P20), and shows that in all but one
(P20) of them the amount of fully assembled CI was lower than
Fig. 1. Effect of chronic rotenone treatment on subcellular superoxide production, residual CI activity and cellular CI expression in human skin fibroblasts—(A)
FCCP-induced redistribution of HEt oxidation products between mitochondria and nucleus. Fibroblasts (CT1, Table 1) were incubated with 10 μM hydroethidine
(HEt) for 10 min at 37 °C, thoroughly washed and visualized using fluorescence microscopy. FCCP (1 μM) was added at the designated time (arrow). Fluorescence
signals were obtained from the indicated compartments and background corrected. (B) Dose-dependency of the effect of chronic (72 h) rotenone treatment on the
accumulation of HEt oxidation products in the indicated compartment (closed symbols) and the residual CI activity (open symbols). Fibroblasts were pretreated with
vehicle or the indicated concentration of rotenone (closed symbols) for 72 h. Residual CI activity (right y-axis) and fluorescence intensity (left y-axis) are expressed as
percentage of vehicle-treated control. The data presented are the average±SEM of 3 independent measurements. (C) Effect of chronic rotenone treatment (100 nM,
72 h) on CI expression. Mitochondrial enriched fractions of vehicle- and rotenone-treated cells were subjected to blue-native electrophoresis and Western blotting.
Intensities of the CI and CII bands were determined by densitometry and expressed as percentage of vehicle-treated control. The data presented are the average±SEM
of three independent experiments. *, significantly different from control.
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Fig. 3. Inverse relationship between superoxide production and fully assembled
CI in fibroblasts of patients with isolated CI deficiency—Measurement of
superoxide production and analysis of fully assembled CI was performed as
described in the caption to Fig. 1. The Western blot shows the decrease in fully
assembled CI in one of the patient cells lines (P4). Linear regression analysis
reveals an inverse correlation between superoxide production and amount of
fully assembled CI for 7 patient cell lines with a known (black symbols) and 6
with a hitherto unknown (open symbols) mutation. Assembly data are from 9
(CT), 1 (P5, P14, P15, P16, P18, P19, P20), 2 (P1, P2, P3, P13), 4 (P4) and 5
(P12) independent experiments. Mean fluorescence intensities (±SEM), number
of cells analyzed and patient numbers are depicted in Table 1.
Fig. 2. Inverse relationship between superoxide production and residual CI
activity in fibroblasts of patients with isolated CI deficiency—Measurement of
superoxide production was performed as described in the caption to Fig. 1.
Fluorescence intensity in the indicated compartment (left y-axis) is expressed as
percentage of vehicle-treated control (CT). Mean values, number of cells
analyzed and patient numbers are depicted in Table 1. Closed and open symbols
represent patient cell lines with a known (13 patients) and hitherto unknown (8
patients) mutation, respectively. Linear regression analysis reveals an inverse
correlation between superoxide production and residual CI activity for the whole
cohort of patient cell lines.
378 S. Verkaart et al. / Biochimica et Biophysica Acta 1772 (2007) 373–381control. Except cell line P20, the cell lines of the other patients
with a hitherto unknown mutation (open symbols) did not differ
from those with a known mutation (closed symbols). Linear
regression analysis revealed that for the whole cohort of patient
cell lines this parameter was negatively related to the cell's
superoxide production (R=−0.62, p=0.017) and positively to
its residual CI activity (R=0.89, p<0.0001).
4. Discussion
Malfunction of the OXPHOS system causes a wide range of
neuromuscular, cardiac, and endocrine disorders and, more
recently, has also been implicated in age-related diseases and
various forms of cancer [3,6,29]. In 40% of the cases of
inherited OXPHOS disease, the deficiency is associated with an
isolated (25%) or combined (15%) defect in CI, the first and
largest complex of the OXPHOS system [19]. At present,
however, there is only very limited information about the
cytopathological effects of a disease-causing reduction in CI
activity. Here, we quantitatively assessed superoxide production
in living skin fibroblasts of a large cohort of 21 patients with
inherited isolated CI deficiency, 13 of which with an established
mutation in one of the nuclear-encoded CI subunits and 8 inwhich the disease causing mutation still has to be established,
and demonstrate an inverse relationship with the amount and
residual activity of this complex. The same inverse relationship
between superoxide production and CI activity was observed in
healthy fibroblasts treated with increasing concentrations of
rotenone. In the latter case, however, the amount of CI increased
rather than decreased, indicating that superoxide production can
increase in the absence of any mutated subunit. Based on the
latter finding we conclude that in isolated human CI deficiency
increased cellular superoxide production is primarily a
consequence of decreased cellular CI activity and not of further
electron leakage due to the presence of a mutated subunit.
In healthy cells, the vast majority (>90%) of reactive oxygen
species is produced as a consequence of oxidative phosphor-
ylation [2,30]. Work on isolated mitochondrial preparations
suggests that CI and CIII are the major contributors to
superoxide production [2,30,31]. In addition, CII can contribute
by donating electrons to CI via reverse electron flow [32,33]. As
far as CI is concerned, single electron reduction of oxygen can
occur at the FMN binding site, the iron–sulfur clusters and/or
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superoxide produced by CI is released into the mitochondrial
matrix, whereas that produced by CIII enters both the matrix
and the intermembrane space [33]. It has been demonstrated that
reverse electron flow can be effectively blocked by CI
inhibitors, leading to a reduction in superoxide production.
Here we show that in all patient cell lines acute addition of
rotenone increased rather than decreased the amount of HEt
oxidation products, indicating that reverse electron flow is not
the underlying cause of increased superoxide production in
isolated human CI deficiency.
In addition to CI and CIII, the tricarboxylic acid cycle
enzyme α-ketoglutarate dehydrogenase can produce significant
amounts of superoxide, especially under conditions that the
NADH level in the matrix is increased [38]. Moreover, other
organelles, such as the endoplasmic reticulum and peroxisomes,
may contribute to the production of superoxide (reviewed in
[39]). Because HEt oxidation products can easily pass
mitochondrial membranes, the method used here to measure
cellular superoxide production does not allow to make a
statement concerning the exact site(s) of HEt oxidation.
Whatever the case may be, the present finding that chronic
rotenone decreased the activity of CI and increased the amount
of HEt oxidation products with virtually the same potency
indicates that a reduction in mitochondrial CI activity is
associated with an increase in cellular superoxide production.
Importantly, because the inhibitor increased rather than
decreased the amount of fully assembled CI, it can be concluded
that the observed increase in superoxide production was not due
to misassembly of the complex.
The same correlation between cellular superoxide production
and residual CI activity was observed within our large cohort of
CI deficient patient cell lines. In this case, however, the decrease
in residual activity was quantitatively correlated with a decrease
in fully assembled CI. In agreement with our results, the
NDUFS1-Q522K mutation has recently been published to be
associated with a marked reduction in CI amount and activity
and a significant increase in mitochondrial superoxide and
derived reactive oxygen species [40]. Taken together, the
present findings may provide first insight into the mechanism of
superoxide production in human CI deficiency in that they
suggest that decreasing numbers of active complexes produce
increasing amounts of superoxide not because of the presence of
a mutated subunit but as a consequence of a decrease in cellular
CI activity. The alternative explanation that increasing numbers
of partially assembled complexes are responsible for the
observed increase in superoxide production is not supported
by the present finding that chronic rotenone treatment increased
rather than decreased the amount of fully assembled CI.
The cohort of patient cell lines used in this study included 13
cell lines with established mutations in nuclear-encoded CI
subunits (see, Table 1). All 6 affected subunits are predicted to
constitute part of the matrix-protruding arm of CI [41]. Five of
them, NDUFV1 (51 kDa), NDUFS1 (75 kDa), NDUFS2
(49 kDa), NDUFS7 (PSST) and NDUFS8 (TYKY), belong to
the group of 14 “central” subunits that are sufficient to perform
all bioenergetic functions of the complex, whereas the remainingone, NDUFS4 (AQDQ), belongs to the large group of accessory
proteins. Except for NDUFS2, the other 4 “central” subunits
carry iron–sulfur clusters responsible for electron transport from
NDUFV1, where NADH is oxidized, to NDUFS7, where
ubiquinone is reduced.With the exception of 5 cell lines carrying
a mutation in NDUFS4 (see below), 7 (P6 was not analyzed) of
the other 8 cell lines displayed a fully assembled complex on a
blue-native gel, the amount of which was decreased to a variable
degree. Irrespective of the affected subunit, this amount was
quantitatively correlated with the cell's residual CI activity,
indicating that primarily the expression of the fully assembled
complex rather than its intrinsic activity is altered. This
conclusion is in agreement with our proposal that the increase
in cellular superoxide production is not a direct consequence of
further electron leakage from complexes containing a mutated
subunit, but of the decrease in cellular CI activity. Importantly,
when patient cells were acutely treated with rotenone, super-
oxide production was even further increased. This indicates that
the rotenone-binding site, which is part of the coenzyme Q
binding site [30,42], is intact in these CI deficient patients.
Regarding the 5 patient cell lines carrying a mutation in
NDUFS4, they all showed a rotenone-sensitive CI activity when
assayed in a mitochondrial enriched fraction. On the other hand,
all 5 cell lines showed only an inactive subcomplex on a blue-
native gel. Previous work revealed the complete absence of any
NDUFS4 in patient cell lines P7 and P11 [43]. Together with the
information that the other 3 patient cell lines of the present study
are either homozygous for a premature stop codon (P8 and P9)
or carry a premature stop codon and a frameshift (P10) and,
therefore, do not express any NDUFS4, these results indicate
that in the absence of NDUFS4 catalytically active complexes
are formed, which are, however, relatively unstable and fall
apart during blue-native electrophoresis. Analysis of the amount
of subcomplex as a measure of the amount of catalytically
active complex in the mitochondrial enriched fraction then
shows that also in these patient cells significantly less
catalytically active complex is formed. In contrast to the present
study, it was recently shown that fibroblasts of a patient with a
nonsense mutation in the first exon of the NDUFS4 gene
(NDUFS4-W15X) produced normal amounts of superoxide
[40]. Similarly, the present study demonstrates that superoxide
production can be increased (P1) or normal (P2) in fibroblasts of
two CI deficient brothers. Both cell lines showed the same
decrease in fully assembled CI and residual CI activity. These
findings indicate that additional factors, such as detoxifying
enzymes and nonenzymatic antioxidants, play a role in
determining net superoxide production. The involvement of
such factors is also evident from the large variation in
superoxide production at any given residual CI activity (Fig. 2).
Finally, our results partially agree with earlier work showing
that superoxide generation was increased in 5 CI deficient
patients, whereas it was not different from control or even lower
than control in another 8 patients [44]. Moreover, in contrast to
the latter study, we found no correlation between the rate of
superoxide production and clinical phenotype (depicted in
Table 1). At present, we have no explanation for these
discrepancies. Major differences are the use of living fibroblasts
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instead of the chemiluminescent probe lucigenin. Both studies
had only two clinical phenotypes in common, Leigh's Disease
(LD) and Fatal Infantile Lactic Acidosis (FILA). In both studies,
the LD patients showed an increase in superoxide, whereas the
two FILA patients investigated in the earlier study showed
either a decrease or no change in superoxide production. Our
study did not include patients displaying Cardiomyopathy with
Cataracts and Hepatomegaly with Renal Tubulopathy, shown in
the previous study to have a decreased and normal rate of
superoxide production, respectively. Obviously, evaluation of
these latter clinical phenotypes is required to be confident that
under all conditions of isolated CI deficiency a decrease in CI
activity is associated with an increase in cellular superoxide
production.
In accordance with the above findings, antioxidants were
found to improve OXPHOS function in superoxide dismutase 2
null mice [45] and fibroblasts of Parkinson's disease patients
[46]. Furthermore, chronic antioxidant treatment was shown to
increase CVactivity and ATP synthesis in cybrids containing the
mtDNA of patients with the T8993G mtDNA mutation
associated with impaired oxidative phosphorylation in NARP
(neuropathy, ataxia and retinitis pigmentosa) and MILS
(maternally inherited Leigh's syndrome) [47]. Likewise, chronic
oral administration of high concentrations of vitamin E was
found to prevent the loss of mitochondrial function and reduce
protein and lipid oxidation in brain and liver of aging mice [48].
These beneficial effects were paralleled by an increased lifespan,
better neurological performance and higher exploratory activity.
Regarding human CI deficiency, patients have been found to
respond differentially to antioxidant treatment (e.g. ref. [49]).
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